Fundraising Fox

Avilar Therapeutics

Waltham, US · Founded 2020 · 5 known investors

avilar-tx.com ↗

Avilar develops protein degrader drugs targeting extracellular and membrane-bound proteins, using a novel class called ATACs that harness endolysosomal degradation machinery. The company focuses on treating serious human diseases where currently undrugged extracellular proteins play a pathogenic role.

AI & Machine LearningBiotechMedical Devicesin /avilar-therapeutics@Avilar_Tx

Founders & leadership

TC
THERESA CAMERONDirector
PH
PAULINA HILLDirector
MF
MARTIN FREEDDirector
ST
STEPHANIE TOZZOExecutive Officer
PG
PHIL GRAHAMExecutive Officer
MD
MILIND DESHPANDEDirector
DN
DAVID NEAFUSExecutive Officer
DG
DANIEL GRAUExecutive Officer, Director
AM
ADAM MUZIKANTExecutive Officer
JR
JOSHUA RESNICKDirector

Investors · 5

Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Medical Excellence CapitalNew York
RA CapitalBoston
Sanofi VenturesCambridge · $5M
OpenSky VenturesreportedLos Angeles

Reported raises · per SEC filings

Form D private placements
▶$75.3MraisedFeb 2023 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • THERESA CAMERONDirector
  • PAULINA HILLDirector
  • MARTIN FREEDDirector
  • STEPHANIE TOZZOExecutive Officer
  • PHIL GRAHAMExecutive Officer
  • MILIND DESHPANDEDirector
  • DAVID NEAFUSExecutive Officer
  • DANIEL GRAUExecutive Officer, Director
  • ADAM MUZIKANTExecutive Officer
  • JOSHUA RESNICKDirector
Offering amount
$75.3M
Amount sold
$75.3M
First sale
Dec 2020
Incorporated
Corporation, Massachusetts, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.